drugset / Trial / NCT00402077
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
Timeline
- Start
- 2006-11
- Primary completion
- 2007-08
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Phentermine | Small molecule | 37.5 mg | Oral |
| Subject | Pramlintide | Peptide | 120 ug | Subcutaneous |
| Subject | Sibutramine | Small molecule | 10 mg | Oral |